- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Episode 42: Establishing a New Drug Therapy
Pharm Exec editors interview Mark Glickman, Chief Commercial Officer of Esperion Therapeutics. Glickman discusses the overall cholesterol-lowering space and how it’s planning to add a new therapeutic option for patients, what it means to establish a new therapy in a statin-dominated market, market research approaches, and more.
Mark Glickman
Pharm Exec editors interview Mark Glickman, Chief Commercial Officer of Esperion Therapeutics. Glickman discusses the overall cholesterol-lowering space and how it’s planning to add a new therapeutic option for patients, what it means to establish a new therapy in a statin-dominated market, market research approaches, and more.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
